You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

205 Results
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
  • everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB - General Benefit
  • exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
PACLitaxel,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020
Regimen
Cancer Type:
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
New Drug Funding Program
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
  • prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cyclophosphamide,
bortezomib (PDRP prior authorization),
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021

Pages